<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38638307</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment.</ArticleTitle><Pagination><StartPage>1367974</StartPage><MedlinePgn>1367974</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1367974</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2024.1367974</ELocationID><Abstract><AbstractText>Corona Virus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has presented unprecedented challenges to the world. Changes after acute COVID-19 have had a significant impact on patients with neurodegenerative diseases. This study aims to explore the mechanism of neurodegenerative diseases by examining the main pathways of central nervous system infection of SARS-CoV-2. Research has indicated that chronic inflammation and abnormal immune response are the primary factors leading to neuronal damage and long-term consequences of COVID-19. In some COVID-19 patients, the concurrent inflammatory response leads to increased release of pro-inflammatory cytokines, which may significantly impact the prognosis. Molecular imaging can accurately assess the severity of neurodegenerative diseases in patients with COVID-19 after the acute phase. Furthermore, the use of FDG-PET is advocated to quantify the relationship between neuroinflammation and psychiatric and cognitive symptoms in patients who have recovered from COVID-19. Future development should focus on aggressive post-infection control of inflammation and the development of targeted therapies that target ACE2 receptors, ERK1/2, and Ca<sup>2+</sup>.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Zhao, Xia, Jiao and Lyu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jinyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Respiratory, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">neuroimaging</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38638307</ArticleId><ArticleId IdType="pmc">PMC11024438</ArticleId><ArticleId IdType="doi">10.3389/fneur.2024.1367974</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Puelles VG, L&#xfc;tgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. . Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. (2020) 383:590&#x2013;2. doi: 10.1056/NEJMc2011400</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. (2022) 399:1303&#x2013;12. doi: 10.1016/S0140-6736(22)00462-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00462-7</ArticleId><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Admon AJ, Iwashyna TJ, Kamphuis LA, Gundel SJ, Sahetya SK, Peltan ID, et al. . Assessment of symptom, disability, and financial trajectories in patients hospitalized for COVID-19 at 6 months. JAMA Netw Open. (2023) 6:e2255795. doi: 10.1001/jamanetworkopen.2022.55795, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.55795</ArticleId><ArticleId IdType="pmc">PMC9929698</ArticleId><ArticleId IdType="pubmed">36787143</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazaal S, Harb J, Rima M, Annweiler C, Wu Y, Cao Z, et al. . The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules. (2022) 27:2903. doi: 10.3390/molecules27092903, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27092903</ArticleId><ArticleId IdType="pmc">PMC9101946</ArticleId><ArticleId IdType="pubmed">35566253</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2022) 22:e102&#x2013;7. doi: 10.1016/S1473-3099(21)00703-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistarini C, Fiabane E, Houdayer E, Vassallo C, Manera MR, Alemanno F. Cognitive and emotional disturbances due to COVID-19: an exploratory study in the rehabiliation setting. Front Neurol. (2021) 12:643646. doi: 10.3389/fneur.2021.643646, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.643646</ArticleId><ArticleId IdType="pmc">PMC8165252</ArticleId><ArticleId IdType="pubmed">34079511</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Brutto OH, Wu S, Mera RM, Costa AF, Recalde BY, Issa NP. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: a longitudinal prospective study nested to a population cohort. Eur J Neurol. (2021) 28:3245&#x2013;53. doi: 10.1111/ene.14775, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14775</ArticleId><ArticleId IdType="pmc">PMC8014083</ArticleId><ArticleId IdType="pubmed">33576150</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemanno F, Houdayer E, Parma A, Spina A, del Forno A, Scatolini A, et al. . COVID-19 cognitive deficits after respiratory assistance in the subacute phase: a COVID-rehabilitation unit experience. PLoS One. (2021) 16:e0246590. doi: 10.1371/journal.pone.0246590, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246590</ArticleId><ArticleId IdType="pmc">PMC7870071</ArticleId><ArticleId IdType="pubmed">33556127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali ST, Kang AK, Patel TR, Clark JR, Perez-Giraldo GS, Orban ZS, et al. . Evolution of neurologic symptoms in non-hospitalized COVID-19 long haulers. Ann Clin Transl Neurol. (2022) 9:950&#x2013;61. doi: 10.1002/acn3.51570, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51570</ArticleId><ArticleId IdType="pmc">PMC9268866</ArticleId><ArticleId IdType="pubmed">35607826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaywant A, Vanderlind WM, Alexopoulos GS, Fridman CB, Perlis RH, Gunning FM. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. (2021) 46:2235&#x2013;40. doi: 10.1038/s41386-021-00978-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-00978-8</ArticleId><ArticleId IdType="pmc">PMC7884062</ArticleId><ArticleId IdType="pubmed">33589778</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo MS, Malsy J, P&#xf6;ttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, et al. . Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. (2020) 2:fcaa205. doi: 10.1093/braincomms/fcaa205, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa205</ArticleId><ArticleId IdType="pmc">PMC7717144</ArticleId><ArticleId IdType="pubmed">33376990</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. . Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 long haulers. Ann Clin Transl Neurol. (2021) 8:1073&#x2013;85. doi: 10.1002/acn3.51350, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Trender W, Chamberlain SR, Jolly AE, Grant JE, Patrick F, et al. . Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. (2021) 39:101044. doi: 10.1016/j.eclinm.2021.101044, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101044</ArticleId><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodanovich MY, Kamaeva DA, Naumova AV. Role of demyelination in the persistence of neurological and mental impairments after COVID-19. Int J Mol Sci. (2022) 23:11291. doi: 10.3390/ijms231911291, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911291</ArticleId><ArticleId IdType="pmc">PMC9569975</ArticleId><ArticleId IdType="pubmed">36232592</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. (2022) 28:2406&#x2013;15. doi: 10.1038/s41591-022-02001-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle D, Heindl MR, Limburg H, van Lam van T, Pilgram O, Moulton H, et al. . TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. (2020) 3:e202000786. doi: 10.26508/lsa.202000786, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202000786</ArticleId><ArticleId IdType="pmc">PMC7383062</ArticleId><ArticleId IdType="pubmed">32703818</ArticleId></ArticleIdList></Reference><Reference><Citation>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV | science. Available at: https://www.science.org (Accessed 2023-11-11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164391</ArticleId><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. . A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. (2020) 94:55&#x2013;8. doi: 10.1016/j.ijid.2020.03.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.062</ArticleId><ArticleId IdType="pmc">PMC7195378</ArticleId><ArticleId IdType="pubmed">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YH, Jiang D, Huang JT. SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. Brain Behav Immun. (2020) 87:149. doi: 10.1016/j.bbi.2020.05.012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7202824</ArticleId><ArticleId IdType="pubmed">32387508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: underestimated damage to nervous system. Travel Med Infect Dis. (2020) 36:101642. doi: 10.1016/j.tmaid.2020.101642, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101642</ArticleId><ArticleId IdType="pmc">PMC7269702</ArticleId><ArticleId IdType="pubmed">32220634</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. . SARS-CoV-2 is associated with changes in brain structure in UK biobank. Nature. (2022) 604:697&#x2013;707. doi: 10.1038/s41586-022-04569-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. . Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. (2021) 24:168&#x2013;75. doi: 10.1038/s41593-020-00758-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zazhytska M, Kodra A, Hoagland DA, Frere J, Fullard JF, Shayya H, et al. . Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia. Cell. (2022) 185:1052&#x2013;1064.e12. doi: 10.1016/j.cell.2022.01.024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.024</ArticleId><ArticleId IdType="pmc">PMC8808699</ArticleId><ArticleId IdType="pubmed">35180380</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann DH, Tsukahara T, Weinreb C, Lipovsek M, van den Berge K, Gong B, et al. . Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. (2020) 6:eabc5801. doi: 10.1126/sciadv.abc5801, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc5801</ArticleId><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat. (2007) 211:117&#x2013;24. doi: 10.1111/j.1469-7580.2007.00748.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2007.00748.x</ArticleId><ArticleId IdType="pmc">PMC2375794</ArticleId><ArticleId IdType="pubmed">17553102</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, R&#xfc;b U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol Aging. (2003) 24:197&#x2013;211. doi: 10.1016/S0197-4580(02)00065-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00065-9</ArticleId><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson's disease: separating the wheat from the chaff. J Parkinsons Dis. (2017) 7:S71&#x2013;85. doi: 10.3233/JPD-1790, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-1790</ArticleId><ArticleId IdType="pmc">PMC5345633</ArticleId><ArticleId IdType="pubmed">28282810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. (2020) 16:636&#x2013;44. doi: 10.1038/s41582-020-0398-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0398-3</ArticleId><ArticleId IdType="pmc">PMC7444680</ArticleId><ArticleId IdType="pubmed">32839585</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuaid C, Brady M, Deane R. SARS-CoV-2: is there Neuroinvasion? Fluids Barriers CNS. (2021) 18:32. doi: 10.1186/s12987-021-00267-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-021-00267-y</ArticleId><ArticleId IdType="pmc">PMC8278192</ArticleId><ArticleId IdType="pubmed">34261487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury B, Sharma A, Satarker S, Mudgal J, Nampoothiri M. Dialogue between neuroinflammation and neurodegenerative diseases in COVID-19. J Environ Pathol Toxicol Oncol. (2021) 40:37&#x2013;49. doi: 10.1615/JEnvironPatholToxicolOncol.2021038365, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/JEnvironPatholToxicolOncol.2021038365</ArticleId><ArticleId IdType="pubmed">34587403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani B, Ghashghayi E, Zendehdel M, Baghbanzadeh A, Khodadadi M. Molecular mechanisms highlighting the potential role of COVID-19 in the development of neurodegenerative diseases. Physiol Int. (2022) 109:135&#x2013;62. doi: 10.1556/2060.2022.00019, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/2060.2022.00019</ArticleId><ArticleId IdType="pubmed">35895572</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Rial J, Rivero-Calle I, Salas A, Martin&#xf3;n-Torres F. Role of monocytes/macrophages in COVID-19 pathogenesis: implications for therapy. Infect Drug Resist. (2020) 13:2485. doi: 10.2147/IDR.S258639, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S258639</ArticleId><ArticleId IdType="pmc">PMC7383015</ArticleId><ArticleId IdType="pubmed">32801787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. . Dysregulation of brain and choroid plexus cell types in severe COVID-19 (published correction appears in nature. 2021; 598(7882): E4). Nature. (2021) 595:565&#x2013;71. doi: 10.1038/s41586-021-03710-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H, Dean LS, Jiyarom B, Khadka V, Deng Y, Nerurukar VR, et al. . Single-cell RNA sequencing reveals characteristics of myeloid cells in pulmonary post-acute sequelae of SARS-CoV-2. bioRxiv. (2023) 31:551349. doi: 10.1101/2023.07.31.551349, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.31.551349</ArticleId><ArticleId IdType="pmc">PMC10800799</ArticleId><ArticleId IdType="pubmed">38259488</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease &#x2013; the gut-brain axis and environmental factors. Nat Rev Neurol. (2015) 11:625&#x2013;36. doi: 10.1038/nrneurol.2015.197</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.197</ArticleId><ArticleId IdType="pubmed">26503923</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson&#x2019;s disease? Evidence from 3 cases. Mov. Disord. Off. J. Mov. Disord. Soc. (2012) 27:716&#x2013;9. doi: 10.1002/mds.25020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25020</ArticleId><ArticleId IdType="pubmed">22550057</ArticleId></ArticleIdList></Reference><Reference><Citation>Arizona Parkinson&#x2019;s Disease Consortium. Beach TG, Adler CH, Sue LI, Vedders L, Lue LF, et al. . Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. (2010) 119:689&#x2013;702. doi: 10.1007/s00401-010-0664-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0664-3</ArticleId><ArticleId IdType="pmc">PMC2866090</ArticleId><ArticleId IdType="pubmed">20306269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, et al. . Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord Off J Mov Disord Soc. (2014) 29:1010&#x2013;8. doi: 10.1002/mds.25776, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25776</ArticleId><ArticleId IdType="pubmed">24395122</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenrich M, Mrdenovic S, Balog M, Tomic S, Zjalic M, Roncevic A, et al. . SARS-CoV-2 dissemination through peripheral nerves explains multiple organ injury. Front Cell Neurosci. (2020) 14:229. doi: 10.3389/fncel.2020.00229, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00229</ArticleId><ArticleId IdType="pmc">PMC7419602</ArticleId><ArticleId IdType="pubmed">32848621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. . Transneuronal propagation of pathologic &#x3b1;-Synuclein from the gut to the brain models Parkinson&#x2019;s disease. Neuron. (2019) 103:627&#x2013;641.e7. doi: 10.1016/j.neuron.2019.05.035, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.05.035</ArticleId><ArticleId IdType="pmc">PMC6706297</ArticleId><ArticleId IdType="pubmed">31255487</ArticleId></ArticleIdList></Reference><Reference><Citation>Leta V, Rodr&#xed;guez-Violante M, Abundes A, Rukavina K, Teo JT, Falup-Pecurariu C, et al. . Parkinson&#x2019;s disease and post-COVID-19 syndrome: the Parkinson&#x2019;s long-COVID Spectrum. Mov. Disord. Off. J. Mov. Disord. Soc. (2021) 36:1287&#x2013;9. doi: 10.1002/mds.28622, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28622</ArticleId><ArticleId IdType="pmc">PMC8250675</ArticleId><ArticleId IdType="pubmed">33890344</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves Andrade M, Souza de Faria R, Avelino Mota Nobre S. COVID-19: can the symptomatic SARS-CoV-2 infection affect the homeostasis of the gut-brain-microbiota axis? Med Hypotheses. (2020) 144:110206. doi: 10.1016/j.mehy.2020.110206, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110206</ArticleId><ArticleId IdType="pmc">PMC7444650</ArticleId><ArticleId IdType="pubmed">33254513</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wu Z, Zhang M, Liu S, Zhou L, Yang C, et al. . The role of the gastrointestinal system in neuroinvasion by SARS-CoV-2. Front Neurosci. (2021) 15:694446. doi: 10.3389/fnins.2021.694446, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.694446</ArticleId><ArticleId IdType="pmc">PMC8283125</ArticleId><ArticleId IdType="pubmed">34276298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Gu L, Ma L, Duan Y. Atlas of ACE2 gene expression reveals novel insights into transmission of SARS-CoV-2. Heliyon. (2021) 7:e05850. doi: 10.1016/j.heliyon.2020.e05850, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e05850</ArticleId><ArticleId IdType="pmc">PMC7762714</ArticleId><ArticleId IdType="pubmed">33392409</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Bao L, Gao H, Xiang Z, Qu Y, Song Z, et al. . Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. Nat Commun. (2020) 11:4400. doi: 10.1038/s41467-020-18149-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18149-6</ArticleId><ArticleId IdType="pmc">PMC7467924</ArticleId><ArticleId IdType="pubmed">32879306</ArticleId></ArticleIdList></Reference><Reference><Citation>Casagrande M, Fitzek A, Spitzer M, P&#xfc;schel K, Glatzel M, Krasemann S, et al. . Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19. Br J Ophthalmol. (2022) 106:1313&#x2013;7. doi: 10.1136/bjophthalmol-2020-318618, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2020-318618</ArticleId><ArticleId IdType="pmc">PMC8042582</ArticleId><ArticleId IdType="pubmed">33836988</ArticleId></ArticleIdList></Reference><Reference><Citation>Penkava J, Muenchhoff M, Badell I, Osterman A, Delbridge C, Niederbuchner F, et al. . Detection of SARS-CoV-2-RNA in post-mortem samples of human eyes. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. (2022) 260:1789&#x2013;97. doi: 10.1007/s00417-021-05529-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-021-05529-x</ArticleId><ArticleId IdType="pmc">PMC8713040</ArticleId><ArticleId IdType="pubmed">34962592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rank A, Tzortzini A, Kling E, Schmid C, Claus R, L&#xf6;ll E, et al. . One year after mild COVID-19: the majority of patients maintain specific immunity, but one in four still suffer from long-term symptoms. J Clin Med. (2021) 10:3305. doi: 10.3390/jcm10153305, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10153305</ArticleId><ArticleId IdType="pmc">PMC8347559</ArticleId><ArticleId IdType="pubmed">34362088</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;hlendick B, Sch&#xf6;nfelder K, Breuckmann K, Elsner C, Babel N, Balfanz P, et al. . ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenet Genomics. (2021) 31:165&#x2013;71. doi: 10.1097/FPC.0000000000000436, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FPC.0000000000000436</ArticleId><ArticleId IdType="pmc">PMC8415730</ArticleId><ArticleId IdType="pubmed">34001841</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, et al. . Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med. (2022) 11:1541. doi: 10.3390/jcm11061541, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11061541</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Arendt-Nielsen L, D&#xed;az-Gil G, G&#xf3;mez-Esquer F, Gil-Crujera A, G&#xf3;mez-S&#xe1;nchez SM, et al. . Genetic association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) polymorphisms with post-COVID symptoms in previously hospitalized COVID-19 survivors. Genes. (2022) 13:1935. doi: 10.3390/genes13111935, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13111935</ArticleId><ArticleId IdType="pmc">PMC9690177</ArticleId><ArticleId IdType="pubmed">36360172</ArticleId></ArticleIdList></Reference><Reference><Citation>The post-hospitalisation COVID-19 study (PHOSP-COVID). Available at: https://www.phosp.org/. (Accessed November 20, 2023)</Citation></Reference><Reference><Citation>Andrews MG, Mukhtar T, Eze UC, Simoneau CR, Ross J, Parikshak N, et al. . Tropism of SARS-CoV-2 for human cortical astrocytes. Proc Natl Acad Sci USA. (2022) 119:e2122236119. doi: 10.1073/pnas.2122236119, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2122236119</ArticleId><ArticleId IdType="pmc">PMC9335272</ArticleId><ArticleId IdType="pubmed">35858406</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. . Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. (2021) 224:1839&#x2013;48. doi: 10.1093/infdis/jiab490, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed WJ. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol. (1996) 142:313&#x2013;22. doi: 10.1006/exnr.1996.0200, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1996.0200</ArticleId><ArticleId IdType="pubmed">8934562</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. (2021) 397:1637&#x2013;45. doi: 10.1016/S0140-6736(21)00676-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal CMS, Jaiswal P, Seth P. SARS-CoV-2, more than a respiratory virus: its potential role in neuropathogenesis. ACS Chem Neurosci. (2020) 11:1887&#x2013;99. doi: 10.1021/acschemneuro.0c00251, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00251</ArticleId><ArticleId IdType="pubmed">32491829</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. (2021) 8:416&#x2013;27. doi: 10.1016/S2215-0366(21)00084-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>2023 Alzheimer's disease facts and figures. Alzheimers Dement. (2023) 19:1598&#x2013;695. doi: 10.1002/alz.13016</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.13016</ArticleId><ArticleId IdType="pubmed">36918389</ArticleId></ArticleIdList></Reference><Reference><Citation>Naughton SX, Raval U, Pasinetti GM. Potential novel role of COVID-19 in Alzheimer&#x2019;s disease and preventative mitigation strategies. J Alzheimers Dis. (2020) 76:21&#x2013;5. doi: 10.3233/JAD-200537, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200537</ArticleId><ArticleId IdType="pmc">PMC8057202</ArticleId><ArticleId IdType="pubmed">32538855</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenesini C, Vignatelli L, Belotti LMB, Baccari F, Calandra-Buonaura G, Cortelli P, et al. . Risk of SARS-CoV-2 infection, hospitalization and death for COVID-19 in people with Parkinson&#x2019;s disease or parkinsonism over a 15-month period: a cohort study. Eur J Neurol. (2022) 29:3205&#x2013;17. doi: 10.1111/ene.15505, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15505</ArticleId><ArticleId IdType="pmc">PMC9350080</ArticleId><ArticleId IdType="pubmed">35841385</ArticleId></ArticleIdList></Reference><Reference><Citation>del Prete E, Francesconi A, Palermo G, Mazzucchi S, Frosini D, Morganti R, et al. . Prevalence and impact of COVID-19 in Parkinson&#x2019;s disease: evidence from a multi-center survey in Tuscany region. J Neurol. (2021) 268:1179&#x2013;87. doi: 10.1007/s00415-020-10002-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10002-6</ArticleId><ArticleId IdType="pmc">PMC7471534</ArticleId><ArticleId IdType="pubmed">32880722</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson&#x2019;s disease: insights from a large Scottish primary care database. BMC Neurol. (2017) 17:126. doi: 10.1186/s12883-017-0904-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0904-4</ArticleId><ArticleId IdType="pmc">PMC5493890</ArticleId><ArticleId IdType="pubmed">28666413</ArticleId></ArticleIdList></Reference><Reference><Citation>Putri C, Hariyanto TI, Hananto JE, Christian K, Situmeang RFV, Kurniawan A. Parkinson&#x2019;s disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. (2021) 87:155&#x2013;61. doi: 10.1016/J.PARKRELDIS.2021.04.019, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PARKRELDIS.2021.04.019</ArticleId><ArticleId IdType="pmc">PMC8065236</ArticleId><ArticleId IdType="pubmed">33931304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferini-Strambi L, Sne M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol. (2021) 268:409&#x2013;19. doi: 10.1007/s00415-020-10070-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10070-8</ArticleId><ArticleId IdType="pmc">PMC7372546</ArticleId><ArticleId IdType="pubmed">32696341</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo MP, Iba M, Nath A, Masliah E, Kim C. Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Exp Mol Med. (2022) 54:447&#x2013;54. doi: 10.1038/s12276-022-00755-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00755-7</ArticleId><ArticleId IdType="pmc">PMC8990637</ArticleId><ArticleId IdType="pubmed">35396576</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, et al. . Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol. (2018) 83:739&#x2013;55. doi: 10.1002/ana.25197, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25197</ArticleId><ArticleId IdType="pubmed">29518260</ArticleId></ArticleIdList></Reference><Reference><Citation>Etemadifar M, Abhari AP, Nouri H, Salari M, Maleki S, Amin A, et al. . Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study. BMC Neurol. (2022) 22:64. doi: 10.1186/s12883-022-02590-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-022-02590-9</ArticleId><ArticleId IdType="pmc">PMC8861623</ArticleId><ArticleId IdType="pubmed">35193507</ArticleId></ArticleIdList></Reference><Reference><Citation>Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, Coles A, Dobson R, et al. . COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord. (2021) 52:102939. doi: 10.1016/j.msard.2021.102939, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.102939</ArticleId><ArticleId IdType="pmc">PMC9585399</ArticleId><ArticleId IdType="pubmed">34010764</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, et al. . Cerebral Micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine. (2020) 25:100484. doi: 10.1016/j.eclinm.2020.100484, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100484</ArticleId><ArticleId IdType="pmc">PMC7396952</ArticleId><ArticleId IdType="pubmed">32838240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Toniolo S, Hampshire A, Husain M. Effects of COVID-19 on cognition and brain health. Trends Cogn Sci. (2023) 27:1053&#x2013;67. doi: 10.1016/j.tics.2023.08.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2023.08.008</ArticleId><ArticleId IdType="pmc">PMC10789620</ArticleId><ArticleId IdType="pubmed">37657964</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez-Cirarda M, Yus M, G&#xf3;mez-Ruiz N, Polidura C, Gil-Mart&#xed;nez L, Delgado-Alonso C, et al. . Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain. (2023) 146:2142&#x2013;52. doi: 10.1093/brain/awac384, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac384</ArticleId><ArticleId IdType="pmc">PMC9620345</ArticleId><ArticleId IdType="pubmed">36288544</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallieri F, Fioravanti V, Bove F, Del Prete E, Meoni S, Grisanti S, et al. . COVID-19 and parkinsonism: a critical appraisal. Biomol Ther. (2022) 12:970. doi: 10.3390/biom12070970</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12070970</ArticleId><ArticleId IdType="pmc">PMC9313170</ArticleId><ArticleId IdType="pubmed">35883526</ArticleId></ArticleIdList></Reference><Reference><Citation>Calculli A, Bocci T, Porcino M, Avenali M, Casellato C, Arceri S, et al. . Parkinson disease following COVID-19: report of six cases. Eur J Neurol. (2023) 30:1272&#x2013;80. doi: 10.1111/ene.1573</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.1573</ArticleId><ArticleId IdType="pubmed">36807419</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. . 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. (2021) 48:2823&#x2013;33. doi: 10.1007/s00259-021-05215-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, et al. . Long COVID hallmarks on 18F FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging. (2021) 48:3187&#x2013;97. doi: 10.1007/s00259-021-05294-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05294-3</ArticleId><ArticleId IdType="pmc">PMC7937050</ArticleId><ArticleId IdType="pubmed">33677642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kas A, Soret M, Pyatigoskaya N, Cecconi M, Aghemo A, Morelli P, et al. . The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. (2021) 48:2543&#x2013;57. doi: 10.1007/s00259-020-05178-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05178-y</ArticleId><ArticleId IdType="pmc">PMC7810428</ArticleId><ArticleId IdType="pubmed">33452633</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez-Guerrero A, Laespada-Garc&#xed;a MI, G&#xf3;mez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Diaz FJ, et al. . Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. (2020) 95:e2109&#x2013;18. doi: 10.1212/WNL.0000000000010282, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010282</ArticleId><ArticleId IdType="pubmed">32641525</ArticleId></ArticleIdList></Reference><Reference><Citation>Morassi M, Palmerini F, Nici S, Magni E, Savelli G, Guerra UP, et al. . SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. (2021) 268:3980&#x2013;7. doi: 10.1007/s00415-021-10560-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10560-3</ArticleId><ArticleId IdType="pmc">PMC8059684</ArticleId><ArticleId IdType="pubmed">33884450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. . A case of probable Parkinson&#x2019;s disease after SARS-CoV-2 infection. Lancet Neurol. (2020) 19:804&#x2013;5. doi: 10.1016/S1474-4422(20)30305-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30305-7</ArticleId><ArticleId IdType="pmc">PMC7494295</ArticleId><ArticleId IdType="pubmed">32949534</ArticleId></ArticleIdList></Reference><Reference><Citation>Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson&#x2019;s disease: facts and fantasy. Lancet Neurol. (2021) 20:94&#x2013;5. doi: 10.1016/S1474-4422(20)30442-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30442-7</ArticleId><ArticleId IdType="pmc">PMC7834123</ArticleId><ArticleId IdType="pubmed">33253627</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine , Neuroinflammation and post-infectious fatigue in individuals with and without COVID-19 (COVFATI). Available at: https://clinicaltrials.gov/ct2/show/NCT05371522, Last updated May 12, 2022, (Accessed on November 20, 2023)</Citation></Reference><Reference><Citation>Koenig T, Smailovic U, Jelic V. Past, present and future EEG in the clinical workup of dementias. Psychiatry Res Neuroimaging. (2020) 306:111182. doi: 10.1016/j.pscychresns.2020.111182, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2020.111182</ArticleId><ArticleId IdType="pubmed">32921526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchetti G, Agosta F, Canu E, Basaia S, Barbieri A, Cardamone R, et al. . Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. J Neurol. (2022) 269:3400&#x2013;12. doi: 10.1007/s00415-022-11047-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11047-5</ArticleId><ArticleId IdType="pmc">PMC8898558</ArticleId><ArticleId IdType="pubmed">35249144</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlanis G, Buoite Stella A, Biaduzzini F, Bellavita G, Frezza NA, Olivo S, et al. . Cognitive deficit in post-acute COVID-19: an opportunity for EEG evaluation? Neurol Sci. (2023) 44:1491&#x2013;8. doi: 10.1007/s10072-023-06615-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-023-06615-0</ArticleId><ArticleId IdType="pmc">PMC9902820</ArticleId><ArticleId IdType="pubmed">36749529</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony AR, Haneef Z. Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. (2020) 83:234&#x2013;41. doi: 10.1016/j.seizure.2020.10.014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.seizure.2020.10.014</ArticleId><ArticleId IdType="pmc">PMC7569418</ArticleId><ArticleId IdType="pubmed">33121875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota T, Gajera PK, Kuroda N. Meta-analysis of EEG findings in patients with COVID-19. Epilepsy Behav. (2021) 115:107682. doi: 10.1016/j.yebeh.2020.107682, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2020.107682</ArticleId><ArticleId IdType="pmc">PMC7833461</ArticleId><ArticleId IdType="pubmed">33342709</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrei Appelt P, Taciana Sisconetto A, Baldo Sucupira KSM, Neto EM, Chagas TJ, Bazan R, et al. . Changes in electrical brain activity and cognitive functions following mild to moderate COVID-19: a one-year prospective study after acute infection. Clin EEG Neurosci. (2022) 53:543&#x2013;57. doi: 10.1177/15500594221103834, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15500594221103834</ArticleId><ArticleId IdType="pmc">PMC9157278</ArticleId><ArticleId IdType="pubmed">35635280</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. . Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. (2023) 329:1934&#x2013;46. doi: 10.1001/jama.2023.8823, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Anglin K, Durstenfeld MS, Martin JN, Kelly JD, Hsue PY, et al. . Effect of Oral Nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. (2022) 7:95&#x2013;103. doi: 10.20411/pai.v7i1.518, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v7i1.518</ArticleId><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Strickland J, Gardner B, Symanzik J, Evanoff BA. Assessing agreement of self-reported and observed physical exposures of the upper extremity. Int J Occup Environ Health. (2010) 16:1&#x2013;10. doi: 10.1179/107735210800546227, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/107735210800546227</ArticleId><ArticleId IdType="pmc">PMC3579613</ArticleId><ArticleId IdType="pubmed">20166314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. . Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study. BMJ. (2022) 377:e069676. doi: 10.1136/bmj-2021-069676, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. . Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection. N Engl J Med. (2022) 386:1207&#x2013;20. doi: 10.1056/NEJMoa2118691, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. (2022) 20:200. doi: 10.1186/s12916-022-02397-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02397-y</ArticleId><ArticleId IdType="pmc">PMC9126103</ArticleId><ArticleId IdType="pubmed">35606843</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson JM, Adams A, Gray LA, Evans A. COVID-19 &#x201c;rebound&#x201d; associated with Nirmatrelvir/ritonavir pre-hospital therapy. J Infect. (2022) 85:436&#x2013;80. doi: 10.1016/j.jinf.2022.06.011, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.06.011</ArticleId><ArticleId IdType="pmc">PMC9212499</ArticleId><ArticleId IdType="pubmed">35718206</ArticleId></ArticleIdList></Reference><Reference><Citation>Extance A. COVID-19: what is the evidence for the antiviral molnupiravir? BMJ. (2022) 377:o926. doi: 10.1136/bmj.o926</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o926</ArticleId><ArticleId IdType="pubmed">35418477</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B, Campbell EA. Molnupiravir: coding for catastrophe. Nat Struct Mol Biol. (2021) 28:706&#x2013;8. doi: 10.1038/s41594-021-00657-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00657-8</ArticleId><ArticleId IdType="pubmed">34518697</ArticleId></ArticleIdList></Reference><Reference><Citation>Samudyata OAO, Malwade S, Rufino de Sousa N, Goparaju SK, Gracias J, Orhan F, et al. . SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol Psychiatry. (2022) 27:3939&#x2013;50. doi: 10.1038/s41380-022-01786-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01786-2</ArticleId><ArticleId IdType="pmc">PMC9533278</ArticleId><ArticleId IdType="pubmed">36198765</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan TM, Patel R, Siddiqui AH. Furosemide. In StatPearls. Treasure Island (FL): StatPearls Publishing; (2023). doi: 10.7717/peerj.9533</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Vilekar P, Yang SP, Gupta M, Oh MI, et al. . Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide. PeerJ. (2020) 8:e9533. doi: 10.7717/peerj.9533</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9533</ArticleId><ArticleId IdType="pmc">PMC7350920</ArticleId><ArticleId IdType="pubmed">32704455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Vilekar P, Huang J, Weaver DF. Furosemide as a probe molecule for the treatment of neuroinflammation in Alzheimer&#x2019;s disease. ACS Chem Neurosci. (2020) 11:4152&#x2013;68. doi: 10.1021/acschemneuro.0c00445, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00445</ArticleId><ArticleId IdType="pubmed">33225679</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang YF, Breitner JCS, Chiu YL, Khachaturian A, Hayden K, Corcoran C, et al. . Use of diuretics is associated with reduced risk of Alzheimer&#x2019;s disease: the Cache County study. Neurobiol Aging. (2014) 35:2429&#x2013;35. doi: 10.1016/j.neurobiolaging.2014.05.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.05.002</ArticleId><ArticleId IdType="pmc">PMC4366136</ArticleId><ArticleId IdType="pubmed">24910391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. J Hypertens. (2016) 34:1027&#x2013;35. doi: 10.1097/HJH.0000000000000868, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000000868</ArticleId><ArticleId IdType="pubmed">26886565</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T, Riederer P, Kuhn W. Aminoadamantanes: from treatment of Parkinson&#x2019;s and Alzheimer&#x2019;s disease to symptom amelioration of long COVID-19 syndrome? Expert Rev Clin Pharmacol. (2023) 16:101&#x2013;7. doi: 10.1080/17512433.2023.2176301</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2023.2176301</ArticleId><ArticleId IdType="pubmed">36726198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Pasangulapati JP, Stover KR, Liu X, Schier SW, et al. . Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer&#x2019;s disease. Eur J Med Chem. (2021) 222:113565. doi: 10.1016/j.ejmech.2021.113565, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.113565</ArticleId><ArticleId IdType="pubmed">34118718</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachel S., Effect of low-dose Lithium therapy on long COVID symptoms: a randomized controlled trial.; clinical trial registration NCT06108297; clinicaltrials.gov, (2023). Available at: https://clinicaltrials.gov/study/NCT06108297 (accessed 2023-11-20)</Citation></Reference><Reference><Citation>Wei HF, Anchipolovsky S, Vera R, Liang G, Chuang DM. Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19. Eur Rev Med Pharmacol Sci. (2022) 26:2201&#x2013;14. doi: 10.26355/eurrev_202203_28369, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202203_28369</ArticleId><ArticleId IdType="pmc">PMC9173589</ArticleId><ArticleId IdType="pubmed">35363371</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine, Neuroinflammation in Alzheimer&#x2019;s Disease . US National Library of medicine, Neuroinflammation in Alzheimer&#x2019;s disease. Available at: https://clinicaltrials.gov/ct2/show/NCT04274998, (Last updated June 1, 2023, Accessed on November 20, 2023)</Citation></Reference><Reference><Citation>Li Q, Wu Y, Chen J, Xuan A, Wang X. Microglia and immunotherapy in Alzheimer&#x2019;s disease. Acta Neurol Scand. (2022) 145:273&#x2013;8. doi: 10.1111/ane.13551</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13551</ArticleId><ArticleId IdType="pubmed">34779509</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Wang Y, Sun Y, Peng G. Neuroinflammation as a potential therapeutic target in Alzheimer&#x2019;s disease. Clin Interv Aging. (2022) 17:665&#x2013;74. doi: 10.2147/CIA.S357558, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S357558</ArticleId><ArticleId IdType="pmc">PMC9064449</ArticleId><ArticleId IdType="pubmed">35520949</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamariz L, Bast E, Klimas N, Palacio A. Low-dose naltrexone improves post-COVID-19 condition symptoms. Clin Ther. (2024) S0149-2918:e3. doi: 10.1016/j.clinthera.2023.12.009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2023.12.009</ArticleId><ArticleId IdType="pubmed">38267326</ArticleId></ArticleIdList></Reference><Reference><Citation>Choubey A, Dehury B, Kumar S, Medhi B, Mondal P. Naltrexone a potential therapeutic candidate for COVID-19. J Biomol Struct Dyn. (2022) 40:963&#x2013;70. doi: 10.1080/07391102.2020.1820379, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1820379</ArticleId><ArticleId IdType="pmc">PMC7544934</ArticleId><ArticleId IdType="pubmed">32930058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabico S, Enani MA, Sheshah E, Aljohani NJ, Aldisi DA, Alotaibi NH, et al. . Effects of a 2-week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate COVID-19: a randomized clinical trial. Nutrients. (2021) 13:2170. doi: 10.3390/nu13072170, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072170</ArticleId><ArticleId IdType="pmc">PMC8308273</ArticleId><ArticleId IdType="pubmed">34202578</ArticleId></ArticleIdList></Reference><Reference><Citation>Melrose J, Smith MM. Natural and semi-synthetic flavonoid anti-SARS-CoV-2 agents for the treatment of long COVID-19 disease and neurodegenerative disorders of cognitive decline. Front Biosci (Elite Ed). (2022) 14:27. doi: 10.31083/j.fbe1404027, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.fbe1404027</ArticleId><ArticleId IdType="pubmed">36575843</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu TT, Yuan BY, Liu GZ. Ginkgolides and bilobalide for treatment of Alzheimer&#x2019;s disease and COVID-19: potential mechanisms of action. Eur Rev Med Pharmacol Sci. (2022) 26:9502&#x2013;10. doi: 10.26355/eurrev_202212_30702, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202212_30702</ArticleId><ArticleId IdType="pubmed">36591860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>